Pregnant women with low risk indicators for fetal chromosomal aneuploidy will be enrolled. Study blood will be collected in the first or second trimester at a scheduled prenatal screening visit, processed to plasma, and stored frozen until analysis. Each pregnancy will be followed until delivery and the birth outcome recorded.
Study Type
OBSERVATIONAL
Enrollment
3,333
Plasma samples obtained from maternal blood will be tested using the SEQureDx Trisomy Test, an in vitro diagnostic test that measures circulating cell-free fetal DNA. The test detects the relative quantity of chromosome 21, which is associated with trisomy 21.
Estimate the false positive rate of SEQureDx Trisomy 21 Test
Time frame: pregnancy outcome
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of South Alabama
Mobile, Alabama, United States
New Horizon Women's Care
Chandler, Arizona, United States
Precision Trials
Phoenix, Arizona, United States
Visions Clinical Research Tuscon
Tucson, Arizona, United States
Descanso OBGYN
Glendale, California, United States
Woodglen Medical Group
Glendora, California, United States
White Memorial GYN/OB Medical Group
Los Angeles, California, United States
Fair Oaks Women's Health
Pasadena, California, United States
IGO Medical Group
San Diego, California, United States
West Coast OBGYN
San Diego, California, United States
...and 17 more locations